US Blocks Copycat Heart Drugs: Patent Wars Heat Up
Published Date: 5/8/2025
Notice
Summary
BioMarin Pharmaceutical is asking the U.S. International Trade Commission to investigate some imported drug products that might be breaking their patent rules. This could lead to stopping those products from being sold in the U.S., affecting companies involved in making or selling these drugs. The investigation started in April 2025 and could change who gets to sell these medicines and when.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in